AU2018256392B2 - Anti-PD-L1 antibody and use thereof - Google Patents

Anti-PD-L1 antibody and use thereof Download PDF

Info

Publication number
AU2018256392B2
AU2018256392B2 AU2018256392A AU2018256392A AU2018256392B2 AU 2018256392 B2 AU2018256392 B2 AU 2018256392B2 AU 2018256392 A AU2018256392 A AU 2018256392A AU 2018256392 A AU2018256392 A AU 2018256392A AU 2018256392 B2 AU2018256392 B2 AU 2018256392B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018256392A
Other languages
English (en)
Other versions
AU2018256392A1 (en
Inventor
Shorena ARCHUADZE
Sergei BARBASHOV
Vasily IGNATIEV
Yan Lavrovsky
Alexey REPIK
Mikhail Samsonov
Ting Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R-PHARM OVERSEAS Inc
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of AU2018256392A1 publication Critical patent/AU2018256392A1/en
Application granted granted Critical
Publication of AU2018256392B2 publication Critical patent/AU2018256392B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018256392A 2017-04-18 2018-04-18 Anti-PD-L1 antibody and use thereof Ceased AU2018256392B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2017/028206 2017-04-18
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (2)

Publication Number Publication Date
AU2018256392A1 AU2018256392A1 (en) 2019-10-17
AU2018256392B2 true AU2018256392B2 (en) 2024-05-16

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018256392A Ceased AU2018256392B2 (en) 2017-04-18 2018-04-18 Anti-PD-L1 antibody and use thereof

Country Status (17)

Country Link
US (1) US20210115143A1 (https=)
EP (1) EP3612565A4 (https=)
JP (2) JP2020517239A (https=)
KR (1) KR102323960B1 (https=)
CN (1) CN110856446A (https=)
AU (1) AU2018256392B2 (https=)
BR (1) BR112019021828B1 (https=)
CA (1) CA3059447A1 (https=)
CL (1) CL2019002953A1 (https=)
CO (1) CO2019012118A2 (https=)
EA (1) EA201900443A1 (https=)
MA (1) MA50038A (https=)
MX (1) MX2019012461A (https=)
MY (1) MY199319A (https=)
PH (1) PH12019502302A1 (https=)
SG (1) SG11201909041SA (https=)
WO (1) WO2018195226A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709B (zh) * 2019-04-11 2024-08-23 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
EP3833691B1 (en) * 2019-04-26 2024-09-25 I-Mab Biopharma Co., Ltd. Human pd-l1 antibodies
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CN116178545B (zh) * 2021-09-24 2025-09-12 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2015061668A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2940242C (en) * 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN117088979A (zh) * 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Also Published As

Publication number Publication date
EP3612565A4 (en) 2021-06-16
EA201900443A1 (ru) 2020-03-06
MA50038A (fr) 2020-07-08
MX2019012461A (es) 2019-12-11
PH12019502302A1 (en) 2020-09-21
JP2020517239A (ja) 2020-06-18
KR20190141169A (ko) 2019-12-23
JP2023025003A (ja) 2023-02-21
SG11201909041SA (en) 2019-11-28
BR112019021828B1 (pt) 2022-09-20
MY199319A (en) 2023-10-24
KR102323960B1 (ko) 2021-11-10
CO2019012118A2 (es) 2020-04-01
BR112019021828A2 (pt) 2020-03-24
WO2018195226A1 (en) 2018-10-25
CA3059447A1 (en) 2018-10-25
CN110856446A (zh) 2020-02-28
AU2018256392A1 (en) 2019-10-17
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
AU2018256392B2 (en) Anti-PD-L1 antibody and use thereof
RU2756236C2 (ru) PD-L1 специфические антитела
JP6163158B2 (ja) Ｃｄ４０ｌに拮抗する抗体ポリペプチド
US11008391B2 (en) Anti-PD-1 antibodies
US12497455B2 (en) Anti-CD3E/BCMA bispecific antibody and use thereof
TWI844684B (zh) 一種抗ceacam5的單殖株抗體及其製備方法和用途
JP2021524268A (ja) Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
KR20220104783A (ko) Cd3 및 bcma에 대한 항체, 및 이로부터 제조된 이중특이적 결합 단백질
JP2014518640A (ja) β−クロトおよびＦＧＦ受容体を含む複合体に結合するヒト抗原結合タンパク質
US20240010721A1 (en) Ror1-targeting antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof
KR102879521B1 (ko) 항-il-27 항체 및 이의 용도
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
TW202124452A (zh) 抗tigit的新型抗體
TW202438528A (zh) 特異性結合Ｃｌａｕｄｉｎ １８．２的抗體及其製法和應用
WO2020058762A1 (en) Antibodies specific to ctla-4 and uses thereof
WO2023174405A1 (zh) Claudin18.2人源化抗体及其应用
US20250289901A1 (en) Anti-cd3e/bcma bispecific antibody and use thereof
EA044327B1 (ru) Антитело к pd-l1 и его применение
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
HK40105152A (zh) 对muc18特异性的抗体
CN119345349A (zh) 抗ox40抗体在制备药物中的用途
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK40060753B (zh) 对muc18特异性的抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired